Login
$KLRS
$1.46 -$0.11 (7.3%) Live

$KLRS 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

Preliminary data from the ongoing Phase 1b/2 study of TH103 in nAMD is now expected in 2H 2027

11 Aug 2026 8-K: Results of Operations and Financial Condition

Patient dosing is ongoing in the Phase 1b/2 study of TH103; preliminary data anticipated in 1H 2027

20 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of July 7, 2026 by and between Kalaris Therapeutics, Inc. (the “Company”), and Liisa Bayko (the “Executive”) (together, the “Parties”).

17 Jul 2026 8-K: Regulation FD Disclosure; Other Events

Forward-Looking Statements & Disclaimer This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as am...

06 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

04 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Kalaris Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders on June 3, 2026. The following is a summary of the matters voted on at that meeting.

12 May 2026 8-K: Results of Operations and Financial Condition

Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be

10 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

17 Mar 2026 8-K: Results of Operations and Financial Condition

Positive initial data reported from Phase 1a Single Ascending Dose study in nAMD in December 2025;

09 Mar 2026 8-K: Regulation FD Disclosure

Forward-Looking Statements & Disclaimer This presentation contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as am...

18 Dec 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 17, 2025, by and among Kalaris Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreem...

17 Dec 2025 8-K: Regulation FD Disclosure; Other Events

Exhibit 99.2 TH103 Phase 1a Initial Data Release December 2025

12 Nov 2025 8-K: Results of Operations and Financial Condition

Phase 1a Single Ascending Dose trial remains on track for initial clinical data to be reported by year end 2025

03 Nov 2025 8-K: Departure/Election of Directors or Officers; Compensation

THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of November 1, 2025 by and between Kalaris Therapeutics, Inc. (the “Company”), and Matthew Gall (the “Executive”) (together, the “Parties”).

13 Aug 2025 8-K: Submission of Matters to a Vote of Security Holders

Kalaris Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders on August 12, 2025. The following is a summary of the matters voted on at that meeting.

13 Aug 2025 8-K: Results of Operations and Financial Condition

Continuing to enroll nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent

20 Jun 2025 8-K: Shareholder Director Nominations; Other Events

To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.

14 May 2025 8-K: Results of Operations and Financial Condition

Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the re...

16 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

THIS EMPLOYMENT AGREEMENT (the “Agreement”), is made as of April 10, 2025 by and between Kalaris Therapeutics, Inc. (the “Company”), and Andrew Oxtoby (the “Executive”) (together, the “Parties”).

04 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation

On April 3, 2025, upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Kalaris Therapeutics, Inc. (the “Company”), the Board elected Leone Patterson to serve as a member ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support